Moreover, and consistent with previous trials, we could confirm that patients showing positive prognostic markers, such as a smaller number of metastatic tumor sites, no melanoma brain metastases and a smaller tumor burden at the time of initial diagnosis are more likely to undergo a prolonged response to BRAF ± MEKi therapy even after treatment discontinuation. Here, BRAF is linked to metastatic neoplasm.